SK bioscience's SKYCellflu, a cell-cultured influenza vaccine, has been approved by Indonesia's Food and Drug Authority.
SK bioscience will invest $3 million in Fina Biosolutions, a Maryland-based conjugate vaccine developer, the Korean company said Tuesday.
SK bioscience is seeking a breakthrough with its shingles vaccine amid anticipated summer demand and longtime rival MSD's withdrawal from the shingles vaccine market.
SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.
The flu season is back in full swing, and so is SK bioscience’s production of Korea’s first and only cell-based influenza vaccine.
SK bioscience swung to a loss in the second quarter of 2023 due to weak vaccine sales and contract manufacturing organization (CMO) orders.
SK bioscience has signed a memorandum of understanding (MOU) with Thailand’s Government Pharmaceutical Organization (GPO) to establish vaccine infrastructure in the Southeast Asian country.
SK bioscience and Sanofi completed the Phase II clinical trial for a pneumococcal vaccine that the companies are jointly developing, the Korean pharmaceutical company said Friday.
SK bioscience has signed an agreement with the Australia-based Peter Doherty Institute for Infection and Immunity to cooperate on influenza vaccine development.
SK bioscience’s SKYCovione, Korea’s first domestically developed Covid-19 vaccine, was listed for emergency use by the World Health Organization (WHO).
Korea JoongAng Daily Sitemap
